Logo image of CYCN

CYCLERION THERAPEUTICS INC (CYCN) Stock Overview

USA - NASDAQ:CYCN - US23255M2044 - Common Stock

2.46 USD
-0.09 (-3.53%)
Last: 9/12/2025, 8:00:01 PM

CYCN Key Statistics, Chart & Performance

Key Statistics
52 Week High9.47
52 Week Low1.27
Market Cap8.22M
Shares3.34M
Float2.29M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.74
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO03-18 2019-03-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CYCN short term performance overview.The bars show the price performance of CYCN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

CYCN long term performance overview.The bars show the price performance of CYCN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CYCN is 2.46 USD. In the past month the price increased by 5.58%. In the past year, price decreased by -15.17%.

CYCLERION THERAPEUTICS INC / CYCN Daily stock chart

CYCN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.62 385.71B
AMGN AMGEN INC 12.67 148.80B
GILD GILEAD SCIENCES INC 14.8 142.13B
VRTX VERTEX PHARMACEUTICALS INC 23.29 101.15B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 61.07B
REGN REGENERON PHARMACEUTICALS 12.27 59.35B
ARGX ARGENX SE - ADR 81.59 46.29B
ONC BEONE MEDICINES LTD-ADR 5.67 38.56B
INSM INSMED INC N/A 30.85B
BNTX BIONTECH SE-ADR N/A 23.26B
NTRA NATERA INC N/A 23.13B
BIIB BIOGEN INC 9.05 21.24B

About CYCN

Company Profile

CYCN logo image Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Company Info

CYCLERION THERAPEUTICS INC

301 Binney Street

Cambridge MASSACHUSETTS 02142 US

CEO: Peter M. Hecht

Employees: 1

CYCN Company Website

CYCN Investor Relations

Phone: 16176217722

CYCLERION THERAPEUTICS INC / CYCN FAQ

What is the stock price of CYCLERION THERAPEUTICS INC today?

The current stock price of CYCN is 2.46 USD. The price decreased by -3.53% in the last trading session.


What is the ticker symbol for CYCLERION THERAPEUTICS INC stock?

The exchange symbol of CYCLERION THERAPEUTICS INC is CYCN and it is listed on the Nasdaq exchange.


On which exchange is CYCN stock listed?

CYCN stock is listed on the Nasdaq exchange.


What is CYCLERION THERAPEUTICS INC worth?

CYCLERION THERAPEUTICS INC (CYCN) has a market capitalization of 8.22M USD. This makes CYCN a Nano Cap stock.


How many employees does CYCLERION THERAPEUTICS INC have?

CYCLERION THERAPEUTICS INC (CYCN) currently has 1 employees.


What are the support and resistance levels for CYCLERION THERAPEUTICS INC (CYCN) stock?

CYCLERION THERAPEUTICS INC (CYCN) has a support level at 2.21 and a resistance level at 2.5. Check the full technical report for a detailed analysis of CYCN support and resistance levels.


Should I buy CYCLERION THERAPEUTICS INC (CYCN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CYCLERION THERAPEUTICS INC (CYCN) stock pay dividends?

CYCN does not pay a dividend.


When does CYCLERION THERAPEUTICS INC (CYCN) report earnings?

CYCLERION THERAPEUTICS INC (CYCN) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of CYCLERION THERAPEUTICS INC (CYCN)?

CYCLERION THERAPEUTICS INC (CYCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.74).


What is the Short Interest ratio of CYCLERION THERAPEUTICS INC (CYCN) stock?

The outstanding short interest for CYCLERION THERAPEUTICS INC (CYCN) is 1.17% of its float. Check the ownership tab for more information on the CYCN short interest.


CYCN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CYCN. When comparing the yearly performance of all stocks, CYCN is a bad performer in the overall market: 88.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CYCN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CYCN. While CYCN seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CYCN Financial Highlights

Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 46.04% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.77%
ROE -22.71%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%79.97%
Sales Q2Q%N/A
EPS 1Y (TTM)46.04%
Revenue 1Y (TTM)N/A

CYCN Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

CYCN Ownership

Ownership
Inst Owners12.26%
Ins Owners24.48%
Short Float %1.17%
Short Ratio0.61